TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19809026
Drug: Venesection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venesection of 2 L of blood (iron depletion)
Study: 9503532
Drug: Molsidomine (M)
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (M) administered for 3 weeks, 4 times a day
Study: 30115593
Drug: Temozolomide (150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (150-200 mg/m2, orally) monotherapy on days 1-5 every 4 weeks for a maximum of 12 cycles
Study: 30115593
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg, intravenously) in combination with temozolomide (150-200 mg/m2, orally)
Study: 30115593
Drug: Temozolomide monotherapy
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide monotherapy
Study: 30115593
Drug: Bevacizumab and
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab and temozolomide combination
Study: 27695978
Drug: Red spinach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red spinach extract (RSE) 1000 mg dose; 90 mg nitrate
Study: 20055772
Drug: Antiparkinson drug
Normalized name: OTHER ANTIPARKINSON DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparkinson drug treatment
Study: 19057272
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg orally twice daily + Docetaxel 75 mg/m2 intravenously on a 21-day cycle
Study: 12207638
Drug: Rifabutin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (300 mg once daily) alone
Study: 11399369
Drug: iodixanol 270
Normalized name: IODIXANOL 270mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol 270 mg I/ml
Study: 8944373
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily (LAN30)
Study: 2011924
Drug: Standard-dose alpha-IFN
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose alpha-IFN (3 MU/day i.m. for 6 months, then 3 MU three times/week for a further 6 months)
Study: 29797695
Drug: Theobromine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine (500 mg d‐1 for 4 weeks)
Study: 29797695
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg d‐1 for 4 weeks)
Study: 10793015
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg) three times daily for 2 weeks
Study: 10793015
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 2 weeks
Study: 8640423
Drug: Individual Child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Child and Parent Cognitive‐Behavioral Treatment (CBT)
Study: 29532784
Drug: Family Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Therapy (FT)
Study: 9286780
Drug: Prostacyclin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin infusion
Study: 28077047
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion (EI) of cefepime 2g IV every 8h with 3h infusion
Study: 22221937
Drug: 10% to
Normalized name: SULFUR 10% TOP BAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% to 20% preemptive warfarin dose reduction
Study: 21161329
Drug: Reactive warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive warfarin dose adjustment
Study: 20187454
Drug: CT‐guided percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT‐guided percutaneous fibrin glue therapy of arachnoid cysts (group B, 30 cases)
Study: 17512795
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen administration for more than 3 months
Study: 17512795
Drug: Short-term oxygen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oxygen administration for 2 weeks
Study: 16138333
Drug: Short-course high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course high-dose methylprednisolone (HDMP) at a daily dose of 30 mg/kg starting 4 days before consolidation therapy
Study: 16138333
Drug: Short-course high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course high-dose methylprednisolone (HDMP)
Study: 7791814
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with cyclosporine and methotrexate
Study: 27004301
Drug: Vitamin D₂
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D₂ (20,000 IU weekly)
Study: 24195210
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment combined with semiconductor laser irradiation
Study: 12594313
Drug: Experimental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapy with doxorubicin, vincristine, cyclophosphamide, dactinomycin, alternating with ifosfamide and etoposide
Study: 12594313
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin
Study: 9102242
Drug: Multiple puncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple puncture and intraarticular antibiotic therapy
Study: 9102242
Drug: Arthrotomy from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrotomy from antero-lateral approach, suction drainage for 24-48 hours, systemic intravenous antibiotic therapy, abduction position of extremity in Frejka pillow and early physiotherapy
Study: 1992877
Drug: Elevated ESR
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated ESR (greater than 30 mm/h) after therapy
Study: 6337624
Drug: Grating stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grating stimulation (CAM therapy)
Study: 29769167
Drug: Post-PCI bivalirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-PCI bivalirudin infusion
Study: 19095215
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by axillary lymph node dissection (ALND)
Study: 12139535
Drug: Intrathecal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal clonidine 150 mg
Study: 12139535
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 150 mg
Study: 18070786
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine 15 mg
Study: 2522919
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion SR 2508 (etanidazole)
Study: 332100
Drug: Intravenous fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fructose treatment
Study: 31937347
Drug: Placebo (48-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (48-hour intravenous infusion starting at 6 to 18 hours after injury)
Study: 19300388
Drug: Soy group
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy group (2 g of soybeans per kilogram body weight for 7 days)
Study: 15557666
Drug: Three-component acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-component acellular pertussis vaccine
Study: 164510
Drug: 1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 percent papaverine cream
Study: 23084254
Drug: Supervised multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised multimodal exercise intervention (9 hours weekly for 6 weeks)
Study: 18849016
Drug: Hemoglobin level
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin level less than 12 g/dL
Study: 18849016
Drug: Neutrophil count
Normalized name: brain-derived neurotrophic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutrophil count 4 x 10(9)/L or greater
Study: 22240283
Drug: Conatumumab-doxorubicin (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conatumumab-doxorubicin (doxorubicin 75 mg/m2 + conatumumab 15 mg/kg every 3 weeks)
Study: 11239634
Drug: Unheated patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unheated patch plus ibuprofen
Study: 17369807
Drug: Nucleotide supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleotide supplement (E)
Study: 9796354
Drug: Ceruletide infusion
Normalized name: ceruletide diethylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceruletide infusion cholescintigraphy
Study: 7705012
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg tid
Study: 7705012
Drug: Ceftazidime 1000
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1000 mg tid for RTIs and 500 mg tid for UTIs
Study: 2533786
Drug: Heat-inactivated hepatitis
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated hepatitis B vaccine + multiple doses of HBIG (Group I)
Study: 2533786
Drug: Heat-inactivated hepatitis
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated hepatitis B vaccine + single dose of HBIG (Group II)
Study: 2533786
Drug: Heat-inactivated hepatitis
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated hepatitis B vaccine only (Group III)
Study: 2533786
Drug: Heat-inactivated hepatitis
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated hepatitis B vaccine only
Study: 405902
Drug: Pilocarpine in
Normalized name: Product containing pilocarpine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine in 0.5% hydroxypropyl-methylcellulose solution
Study: 405902
Drug: Pilocarpine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (both formulations)
Study: 28697789
Drug: Intramuscular or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular or intra-arterial injection of 40 ml BM-MNC concentrate
Study: 21989078
Drug: Metformin 1
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1 g, twice daily
Study: 14586213
Drug: Bryostatin-1 25
Normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin-1 25 mug/m(2) as a 1-h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I)
Study: 10814771
Drug: Haloperidol 25
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 25 mg/day
Study: 10587284
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg/day + Lorazepam 4 mg/day
Study: 10587284
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg/day + Placebo
Study: 1659980
Drug: Granisetron (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (40 micrograms/kg intravenously before chemotherapy, with up to two further doses daily of 40 micrograms/kg if necessary)
Study: 10919583
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.5 g twice daily
Study: 20816833
Drug: formoterol/beclomethasone 12/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol/beclomethasone 12/200 μg Modulite
Study: 20816833
Drug: formoterol/budesonide 9/320
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol/budesonide 9/320 μg Turbuhaler
Study: 12838857
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial chemotherapy and radiotherapy (A group)
Study: 27504014
Drug: 6-month, culturally
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month, culturally tailored, U.S. Diabetes Prevention Program-based lifestyle curriculum plus stepwise addition of metformin (500 mg, twice daily)
Study: 2197911
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (600 mg by inhalation using a Respirgard II nebulizer)
Study: 2197911
Drug: Intravenous pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pentamidine
Study: 265082
Drug: Topical painting
Normalized name: Castellani Paint Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical painting with potassium fluoride solution containing Al-, Fe-, and Mn-ions
Study: 265082
Drug: Topical painting
Normalized name: Castellani Paint Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical painting with 0.2% NaF-solution
Study: 7044620
Drug: Oestrogen/gestagen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen/gestagen alone or in combination with 1,25(OH)2D3
Study: 25223266
Drug: MF59-adjuvanted trivalent
Normalized name: Influenza, adjuvanted, trivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted trivalent subunit vaccine (aTIV)
Study: 25223266
Drug: TIV-2 (split
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIV-2 (split virion vaccine)
Study: 25223266
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three vaccines (aTIV, TIV-1, TIV-2)
Study: 6373441
Drug: Nimesulide 100
Normalized name: nimesulide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 100 mg
Study: 22421470
Drug: Tramadol chlorhydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol chlorhydrate 100 mg
Study: 19079943
Drug: HCA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCA (2 g)
Study: 19079943
Drug: ETO (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETO (320 mg)
Study: 15179192
Drug: Intrahepatic cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrahepatic cisplatin at 125 mg/m
Study: 31162031
Drug: Rituximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (5 x 500 mg until month 18)
Study: 31162031
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg per day, gradually decreased between month 12 and 22)
Study: 28454498
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg (once daily)
Study: 22231013
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human albumin (HA) 20 gr infused over 1 hour
Study: 22231013
Drug: Oral cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cabergoline (Cb2) 0.5 mg per day for 7 days starting on oocyte pickup day
Study: 17456651
Drug: Cumulative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative morphine administration
Study: 12140475
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate spray (FP), 50 microg two dose unit sprays, 4 times daily for 6 weeks
Study: 12140475
Drug: Betamethasone sodium
Normalized name: Betamethasone Sodium Phosphate
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone sodium phosphate mouthrinse (BSP), 500 microg, 4 times daily for 6 weeks
Study: 7876615
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (0, 1, and 12 months schedule for adults; 0, 1, and 6; 0, 1, and 2; or 0, 1, and 12 months for children)
Study: 30901440
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (control group)
Study: 30901440
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Vitamin D3 supplement (treatment group)
Study: 30901440
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Vitamin D3 supplement (treatment group)
Study: 28608438
Drug: NUTRITION (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRITION (oral nutritional supplementation enriched with leucine, vitamin D, and omega-3 fatty acids)
Study: 26534930
Drug: Dopamine replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine replacement therapy (DRT)
Study: 26534930
Drug: No dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dopamine replacement therapy (not on DRT)
Study: 23026180
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg/day
Study: 18923109
Drug: Risk behaviors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk behaviors including frequent public drunkenness, early age of illicit drug use, involvement in the drug economy, tattooing, injecting drugs, unprotected sex
Study: 11859651
Drug: Levocetirizine 2.5
Normalized name: Levocetirizine 2.5mg/5mL Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 2.5 mg
Study: 19860762
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg
Study: 23441762
Drug: Levocetirizine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 10 mg
Study: 3429102
Drug: 5-MOP Re-PUVA
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-MOP Re-PUVA with daily oral etretinate
Study: 20194702
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg posaconazole oral suspension twice daily for 8 days with a high-fat meal
Study: 10511057
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg midazolam intravenously
Study: 10511057
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg midazolam orally
Study: 2429908
Drug: inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inosine pranobex (Imunovir) with conventional treatment
Study: 26081179
Drug: Single maximal
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single maximal inhalation with breath-hold (200 μg salbutamol)
Study: 26081179
Drug: 5 tidal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 tidal breaths (200 μg salbutamol)
Study: 11049140
Drug: Exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise treatment
Study: 18971135
Drug: Bupivacaine-soaked Spongostan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-soaked Spongostan plus local lignocaine infiltration 1% up to 20 mL
Study: 18971135
Drug: Local lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local lignocaine infiltration 1% up to 20 mL
Study: 12657237
Drug: Peritoneal dialysis
Normalized name: Peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal dialysis solution (1.5% dextrose)
Study: 31771756
Drug: Multiple barriers
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple barriers to adherence (e.g., forgetfulness, health beliefs)
Study: 21646910
Drug: Lactulose 30-60
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose 30-60 ml twice per day (GpB)
Study: 21646910
Drug: Probiotics 110
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics 110 billion CFU twice per day (GpC)
Study: 21646910
Drug: L-ornithine L-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine L-aspartate (LOLA) 6 g three times per day (GpD)
Study: 21646910
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (GpA)
Study: 16761194
Drug: ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe (10 mg/day for 90 days)
Study: 11430965
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg and vaginal misoprostol 800 microg (used 48 hours after mifepristone)
Study: 11430965
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol inserted at 1, 2, or 3 days after mifepristone administration
Study: 1351405
Drug: Neuroleptic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic drugs
Study: 9468354
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with neuroleptics
Study: 9468354
Drug: Noncompliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncompliance with medication
Study: 9468354
Drug: Current drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current drug abuse
Study: 3226418
Drug: Continuous hyperthermic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperthermic peritoneal perfusion (CHPP) with an anticancer drug
Study: 25185603
Drug: Pseudoephedrine ER
Normalized name: pseudoephedrine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine ER 120 mg
Study: 8813873
Drug: Imipramine 25
Normalized name: trimipramine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 25 mg
Study: 24822235
Drug: Cyclobenzaprine 10
Normalized name: cyclobenzaprine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 10 mg
Study: 22037770
Drug: Cannabis dose
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis dose
Study: 22037770
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in cannabis dose